Author Response

Authors’ Response on “Rise in Neonatal Abstinence Syndrome Rate Is Associated with Rise in Buprenorphine Prescription Numbers”

Authors: Summer Shore, BS, Nicole Lewis, PhD, Martin Olsen, MD

Abstract

We appreciate the interest in our article “Rise in Neonatal Abstinence Syndrome Rate Is Associated with Increase in Buprenorphine Prescription Numbers,” which appeared in the December 2023 issue of the Southern Medical Journal and take this opportunity to provide additional information. 

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Shore S, Lewis N, Olsen M. Rise in neonatal abstinence syndrome rate is associated with increase in buprenorphine prescription numbers. South Med J 2023;116:930–937.
 
2. US Food and Drug Administration. FDA analysis of long-term trends in prescription opioid analgesic products: quantity, sales, and price trends. https://www.fda.gov/files/about%20fda/published/FDA-Analysis-of-Long-Term-Trends-in-Prescription-Opioid-Analgesic-Products--Quantity--Sales--and-Price-Trends.pdf. Published March 1, 2018. Accessed May 3, 2024.
 
3. Suboxone sublingual film [package insert]. North Chesterfield, VA: Indivior UK; 2002.
 
4. American College of Obstetrics and Gynecology, Committee on Obstetric Practice; American Society of Addiction Medicine. Opioid use and opioid use disorder in pregnancy. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in-pregnancy. Published August 2017. Accessed March 28, 2024.
 
5. Olsen M. Prevention of neonatal abstinence syndrome in an outpatient prenatal buprenorphine tapering program. South Med J 2020;113:553–558.
 
6. Suarez EA, Huybrechts KF, Straub L, et al. Buprenorphine versus methadone for opioid use disorder in pregnancy. N Engl J Med 2022; 387:2033–2044.
 
7. Shah D, Chroust A, Olsen M. Does weaning of buprenorphine in pregnancy (in outpatient setting) improve neonatal and maternal outcome? Obstet Gynecol 2023;141(5 Suppl):4S–5S.
 
8. Tennessee Department of Health, Division of Family Health and Wellness. Neonatal abstinence syndrome surveillance annual report, 2021. https://www.tn.gov/content/dam/tn/health/documents/NAS%20Annual%20Report%202021%20Final.pdf. Published 2022. Accessed March 28, 2024.
 
9. Tennessee Department of Health. Neonatal abstinence syndrome. Data and reports. https://www.tn.gov/health/health-program-areas/fhw/neonatal-abstinence-syndrome-/data-and-reports.html. Accessed March 28, 2024.